

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549  
FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **August 18, 2008**

**iBioPharma, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**000-53125**

(Commission File Number)

**26-2797813**

(IRS Employer Identification No.)

**9 Innovation Way, Suite 100**

**Newark, Delaware**

(Address of Principal Executive Offices)

**19711**

(Zip Code)

**(302) 355-0650**

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 1.01. Entry into a Material Definitive Agreement.**

iBioPharma, Inc. (the “Company”) announced that it began trading on the OTC Bulletin Board under the symbol “IBPM” subsequent to the completion of the spin-off from its former parent, Integrated BioPharma, Inc. (NasdaqGM:INBP) to the shareholders of record of INBP on August 12, 2008.

A copy of the press release issued by the Company is attached as Exhibit 99.1 hereto.

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated August 18, 2008

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

**IBIOPHARMA, INC.**

Date: August 19, 2008

By: /s/ Dina Masi  
Dina Masi  
Interim Chief Financial Officer



NEWS RELEASE for August 18, 2008

Contact: Dina Masi, Interim CFO  
Jeffrey Leach, Investor Relations  
iBioPharma, Inc.  
j.leach@ibiopharma.com  
888.319.6962

**IBIOPHARMA, INC. ANNOUNCES COMMENCEMENT OF TRADING ON THE OTC BULLETIN BOARD**

NEWARK, DE, August 18, 2008 -- iBioPharma, Inc. (OTCBB:IBPM) today announced that it began trading on the OTC Bulletin Board under the symbol "IBPM" subsequent to the completion of the spin-off from its former parent, Integrated BioPharma, Inc. (NasdaqGM:INBP) to the shareholders of record of INBP on August 12, 2008.

**About iBioPharma, Inc. (IBPM)**

iBioPharma, has developed a novel, proprietary platform technology for the rapid, efficient and economical manufacture of biopharmaceuticals, including vaccine antigens, antibodies and other therapeutic proteins. iBioPharma has established an exclusive commercial relationship with the Fraunhofer USA Center for Molecular Biotechnology and the lead product candidates from the joint program include influenza vaccines and an antiviral therapeutic for treatment of influenza. Further information is available at [www.ibiopharma.com](http://www.ibiopharma.com)

Statements included in this release related to iBioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.